Google
×
SCT from an allogeneic donor provides an additional immunologic graft-versus-myeloma effect resulting in more frequent and durable responses. Several ...
People also ask
Jun 20, 2013 · Long-term outcome in patients with multiple myeloma was better with auto/RICallo as compared with auto only and the auto/RICallo approach seemed to overcome ...
Missing: (ASCT) ASCT SCT donor untreated preliminary controlled
Autologous stem cell transplantation (ASCT) is considered the gold standard in the frontline therapy of younger patients with multiple myeloma because it ...
May 6, 2010 · Autologous stem cell transplantation (ASCT) is considered the gold standard in the frontline therapy of younger patients with multiple myeloma.
Jul 1, 2024 · MEDICAL POLICY CRITERIA. I. Autologous hematopoietic cell transplantation may be considered medically necessary to treat multiple myeloma or ...
Jan 1, 2007 · Conversely, results from myeloablative allogeneic stem cell transplantation remain disappointing due to high transplantation-related mortality, ...
Herein, potential treatments beyond ASCT (planned consolidation or maintenance), allo-HCT, and emerging immune therapies, are discussed.
Missing: identical | Show results with:identical
Mar 16, 2022 · Second transplants for multiple myeloma relapsing after a previous autotransplant-reduced-intensity allogeneic vs autologous transplantation.
Missing: identical | Show results with:identical
Tandem autologous (ASCT)/allogeneic reduced intensity conditioning transplantation (RIC) with identical sibling donor versus ASCT in previously untreated ...
Single Autologous Stem Cell Transplantation · High-dose therapy with melphalan and ASCT for MM was associated with improved CR rates and prolongation of overall ...